Cargando…

Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis

BACKGROUND: Macrophage migration inhibitory factor (MIF) has recently emerged as an important cytokine possibly linking rheumatoid arthritis (RA) and atherogenesis. Because atherogenesis is accelerated in RA this study was conducted to investigate whether anti-tumour necrosis factor (TNF) therapy co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wijbrandts, C A, van Leuven, S I, Boom, H D, Gerlag, D M, Stroes, E G S, Kastelein, J J P, Tak, P P
Formato:	Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2008
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2703704/ https://www.ncbi.nlm.nih.gov/pubmed/18723565 http://dx.doi.org/10.1136/ard.2007.086728

Ejemplares similares

Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis
por: Klaasen, R., et al.
Publicado: (2012)

TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade
por: van Kuijk, A W R, et al.
Publicado: (2009)

Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss
por: Wijbrandts, C A, et al.
Publicado: (2008)

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
por: Harrold, Leslie R, et al.
Publicado: (2015)

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor α expression in the synovium
por: Wijbrandts, C A, et al.
Publicado: (2008)

Overnight variations in cortisol, interleukin 6, tumour necrosis factor α and other cytokines in people with rheumatoid arthritis
por: Perry, M G, et al.
Publicado: (2009)

Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis
por: Low, Audrey S L, et al.
Publicado: (2017)

Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumab
por: Herenius, M M J, et al.
Publicado: (2011)

Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis
por: Potter, C, et al.
Publicado: (2009)

Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study
por: Song, Yeo-Jin, et al.
Publicado: (2022)

Monocyte Scintigraphy in Rheumatoid Arthritis: The Dynamics of Monocyte Migration in Immune-Mediated Inflammatory Disease
por: Thurlings, Rogier M., et al.
Publicado: (2009)

Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Mercer, Louise K, et al.
Publicado: (2015)

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register
por: Harrison, M J, et al.
Publicado: (2008)

Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment
por: Tan, Rachael J L, et al.
Publicado: (2010)

Macrophage migration inhibitory factor and DJ-1 in gastric cancer: differences between high-incidence and low-incidence areas
por: Shimwell, N J, et al.
Publicado: (2012)

Smoking and overweight determine the likelihood of developing rheumatoid arthritis
por: de Hair, Maria J H, et al.
Publicado: (2013)

Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years
por: Rahman, Mahboob U, et al.
Publicado: (2011)

Anti-TNF Therapy Reduces Serum Levels of Chemerin in Rheumatoid Arthritis: A New Mechanism by Which Anti-TNF Might Reduce Inflammation
por: Herenius, Marieke M. J., et al.
Publicado: (2013)

Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
por: Keystone, E C, et al.
Publicado: (2008)

Prescriber preference for a particular tumour necrosis factor antagonist drug and treatment discontinuation: population-based cohort
por: Fisher, Anat, et al.
Publicado: (2014)

Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
por: Finckh, A, et al.
Publicado: (2010)

Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor–treated rheumatoid arthritis patients
por: Hamann, Philip D H, et al.
Publicado: (2019)

Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Mercer, Louise K, et al.
Publicado: (2017)

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
por: Schiff, M, et al.
Publicado: (2009)

Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis
por: Leandro, Maria J
Publicado: (2009)

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
por: Emery, P, et al.
Publicado: (2008)

Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis
por: Glossop, John R, et al.
Publicado: (2005)

Synovial Tissue Response to Treatment in Rheumatoid Arthritis
por: Vieira-Sousa, Elsa, et al.
Publicado: (2011)

Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers
por: Delcoigne, Benedicte, et al.
Publicado: (2023)

Macrophage migration inhibitory factor polymorphism and the risk of ulcerative colitis and Crohn's disease in Asian and European populations: a meta-analysis
por: Hao, Ning-Bo, et al.
Publicado: (2013)

The Features of the Synovium in Early Rheumatoid Arthritis According to the 2010 ACR/EULAR Classification Criteria
por: van de Sande, Marleen G. H., et al.
Publicado: (2012)

Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study
por: Smolen, Josef S, et al.
Publicado: (2014)

Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor
por: Ernestam, Sofia, et al.
Publicado: (2006)

Macrophage migration inhibitory factor: a potential therapeutic target for rheumatoid arthritis
por: Kim, Kyoung-Woon, et al.
Publicado: (2016)

Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers
por: Di Minno, Matteo Nicola Dario, et al.
Publicado: (2014)

Anti-tumour necrosis factor alpha treatment in patients affected by rheumatoid arthritis with anti-Ro/SSA antibodies
por: Cavazzana, I, et al.
Publicado: (2005)

Towards prevention of autoantibody-positive rheumatoid arthritis: from lifestyle modification to preventive treatment
por: Gerlag, Danielle M., et al.
Publicado: (2016)

Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort
por: Benson, V S, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_kd6jgqsguacu5gq72ee6vqf8i8